Skip to main content
NCBI home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 1997 Jul;77(1):F32–F35. doi: 10.1136/fn.77.1.f32

Pulmonary function changes after nebulised and intravenous frusemide in ventilated premature infants

V Prabhu, M Keszler, R Dhanireddy
PMCID: PMC1720662  PMID: 9279180

Abstract

AIMS—To compare the effects of a single dose of frusemide administered either intravenously or by nebulisation on pulmonary mechanics in premature infants with evolving chronic lung disease.
METHODS—The effect of frusemide on pulmonary mechanics was studied at a median postnatal age of 23 (range 14-52) days in 19 premature infants at 24 to 30 weeks gestational age, who had been dependent on mechanical ventilation since birth. Frusemide (1 mg/kg/body weight) was administered, in random order, intravenously and by nebulisation, on two separate occasions 24 hours apart. Pulmonary function studies were performed before and at 30, 60, and 120 minutes after administration of frusemide. Urine was collected for six hours immediately before and for six hours after administration of frusemide. 
RESULTS—Nebulised frusemide increased the tidal volume 31(SE 11.5)% and compliance 34 (SE 12)% after two hours, whereas no change in either was noted for up to two hours after intravenous frusemide administration. Neither intravenous nor nebulised frusemide had any effect on airway resistance. Six hour urine output increased from a mean (SE) of 3.3 (0.4) ml/kg/hour to 5.9 (0.8) ml/kg/hour following intravenous frusemide administration while nebulised frusemide had no effect on urine output. Urinary sodium, potassium, and chloride losses were also significantly higher after intravenous frusemide, whereas nebulised frusemide did not increase urinary electrolyte losses.
CONCLUSION—Single dose nebulised frusemide improves pulmonary function in premature infants with evolving chronic lung disease without adverse effects on fluid and electrolyte balance.

 Keywords: inhaled frusemide; pulmonary mechanics; chronic lung disease of prematurity

Full Text

The Full Text of this article is available as a PDF (102.2 KB).

Figure 1  .

Figure 1  

Open in a new tab

Per cent changes from baseline values in tidal volume, compliance, and airway resistance after intravenous and nebulised frusemide administration. Bold line represents intravenous, and shaded line, nebulised route. Data are mean (SE) B= before frusemide administration.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali J., Chernicki W., Wood L. D. Effect of furosemide in canine low-pressure pulmonary edema. J Clin Invest. 1979 Nov;64(5):1494–1504. doi: 10.1172/JCI109608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anderson S. D., He W., Temple D. M. Inhibition by furosemide of inflammatory mediators from lung fragments. N Engl J Med. 1991 Jan 10;324(2):131–131. doi: 10.1056/NEJM199101103240218. [DOI] [PubMed] [Google Scholar]
  3. Beeram M. R., Dhanireddy R. Urinalysis: direct versus diaper collection. Clin Pediatr (Phila) 1991 May;30(5):278–280. doi: 10.1177/000992289103000502. [DOI] [PubMed] [Google Scholar]
  4. Bhutani V. K., Sivieri E. M., Abbasi S., Shaffer T. H. Evaluation of neonatal pulmonary mechanics and energetics: a two factor least mean square analysis. Pediatr Pulmonol. 1988;4(3):150–158. doi: 10.1002/ppul.1950040306. [DOI] [PubMed] [Google Scholar]
  5. Bianco S., Pieroni M. G., Refini R. M., Robuschi M., Vaghi A., Sestini P. Inhaled loop diuretics as potential new anti-asthmatic drugs. Eur Respir J. 1993 Jan;6(1):130–134. [PubMed] [Google Scholar]
  6. Blanchard P. W., Brown T. M., Coates A. L. Pharmacotherapy in bronchopulmonary dysplasia. Clin Perinatol. 1987 Dec;14(4):881–910. [PubMed] [Google Scholar]
  7. Bland R. D. Edema formation in the newborn lung. Clin Perinatol. 1982 Oct;9(3):593–611. [PubMed] [Google Scholar]
  8. Brown E. R., Stark A., Sosenko I., Lawson E. E., Avery M. E. Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr. 1978 Jun;92(6):982–984. doi: 10.1016/s0022-3476(78)80382-5. [DOI] [PubMed] [Google Scholar]
  9. Foresi A., Pelucchi A., Mastropasqua B., Cavigioli G., Carlesi R. M., Marazzini L. Effect of inhaled furosemide and torasemide on bronchial response to ultrasonically nebulized distilled water in asthmatic subjects. Am Rev Respir Dis. 1992 Aug;146(2):364–368. doi: 10.1164/ajrccm/146.2.364. [DOI] [PubMed] [Google Scholar]
  10. Kao L. C., Warburton D., Cheng M. H., Cedeño C., Platzker A. C., Keens T. G. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. Pediatrics. 1984 Jul;74(1):37–44. [PubMed] [Google Scholar]
  11. Moscato G., Dellabianca A., Falagiani P., Mistrello G., Rossi G., Rampulla C. Inhaled furosemide prevents both the bronchoconstriction and the increase in neutrophil chemotactic activity induced by ultrasonic "fog" of distilled water in asthmatics. Am Rev Respir Dis. 1991 Mar;143(3):561–566. doi: 10.1164/ajrccm/143.3.561. [DOI] [PubMed] [Google Scholar]
  12. Nichol G. M., Alton E. W., Nix A., Geddes D. M., Chung K. F., Barnes P. J. Effect of inhaled furosemide on metabisulfite- and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects. Am Rev Respir Dis. 1990 Sep;142(3):576–580. doi: 10.1164/ajrccm/142.3.576. [DOI] [PubMed] [Google Scholar]
  13. O'Connor B. J., Chung K. F., Chen-Worsdell Y. M., Fuller R. W., Barnes P. J. Effect of inhaled furosemide and bumetanide on adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects. Am Rev Respir Dis. 1991 Jun;143(6):1329–1333. doi: 10.1164/ajrccm/143.6.1329. [DOI] [PubMed] [Google Scholar]
  14. O'Donnell W. J., Rosenberg M., Niven R. W., Drazen J. M., Israel E. Acetazolamide and furosemide attenuate asthma induced by hyperventilation of cold, dry air. Am Rev Respir Dis. 1992 Dec;146(6):1518–1523. doi: 10.1164/ajrccm/146.6.1518. [DOI] [PubMed] [Google Scholar]
  15. Patel H., Yeh T. F., Jain R., Pildes R. Pulmonary and renal responses to furosemide in infants with stage III-IV bronchopulmonary dysplasia. Am J Dis Child. 1985 Sep;139(9):917–919. doi: 10.1001/archpedi.1985.02140110071032. [DOI] [PubMed] [Google Scholar]
  16. Pavord I. D., Wisniewski A., Tattersfield A. E. Inhaled frusemide and exercise induced asthma: evidence of a role for inhibitory prostanoids. Thorax. 1992 Oct;47(10):797–800. doi: 10.1136/thx.47.10.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Polosa R., Lau L. C., Holgate S. T. Inhibition of adenosine 5'-monophosphate- and methacholine-induced bronchoconstriction in asthma by inhaled frusemide. Eur Respir J. 1990 Jun;3(6):665–672. [PubMed] [Google Scholar]
  18. Rastogi A., Luayon M., Ajayi O. A., Pildes R. S. Nebulized furosemide in infants with bronchopulmonary dysplasia. J Pediatr. 1994 Dec;125(6 Pt 1):976–979. doi: 10.1016/s0022-3476(05)82018-9. [DOI] [PubMed] [Google Scholar]
  19. Rush M. G., Engelhardt B., Parker R. A., Hazinski T. A. Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. J Pediatr. 1990 Jul;117(1 Pt 1):112–118. doi: 10.1016/s0022-3476(05)82458-8. [DOI] [PubMed] [Google Scholar]
  20. Rush M. G., Hazinski T. A. Current therapy of bronchopulmonary dysplasia. Clin Perinatol. 1992 Sep;19(3):563–590. [PubMed] [Google Scholar]
  21. Spitzer A. R., Fox W. W., Delivoria-Papadopoulos M. Maximum diuresis--a factor in predicting recovery from respiratory distress syndrome and the development of bronchopulmonary dysplasia. J Pediatr. 1981 Mar;98(3):476–479. doi: 10.1016/s0022-3476(81)80728-7. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES